Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H37N5O5S.2ClH |
Molecular Weight | 604.589 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CCCOC1=C(C=C(C=C1)S(=O)(=O)N2CCN(CCO)CC2)C3=NC(=O)C4=C(N3)C(CCC)=CN4CC
InChI
InChIKey=CKPHITUXXABKDL-UHFFFAOYSA-N
InChI=1S/C26H37N5O5S.2ClH/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32;;/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33);2*1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C26H37N5O5S |
Molecular Weight | 531.667 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27034723Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17640490
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27034723
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17640490
The inhibition of cyclic nucleotide Phosphodiesterase type 5 (PDE5) has been clinically validated as an effective treatment for erectile dysfunction. One of them is mirodenafil (formerly known as SK-3530) approved only in Korea. This drug was developed by SK Chemicals and marketed under the trade name Mvix.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17640490/
Curator's Comment: Known to be CNS penetrant in rarts. Human data not available
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27034723 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Mvix Approved UseTreatment of erectile dysfunction(ED) |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. | 2007 |
|
Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. | 2007 Aug |
|
Validation of a HPLC method for the quantification and purity determination of SK3530 in drug substance and tablet. | 2007 Feb 19 |
|
Formation of supramolecular hydrogels with controlled microstructures and stability via molecular assembling in a two-component system. | 2007 Mar 1 |
|
Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. | 2007 Sep 21 |
|
Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil. | 2008 Jan |
|
Editorial comment on: chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. | 2008 Jun |
|
Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. | 2008 Jun |
|
The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury. | 2008 Nov |
|
Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. | 2008 Nov |
|
Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. | 2008 Sep |
|
The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. | 2009 Dec |
|
Determination of mirodenafil and sildenafil in the plasma and corpus cavernous of SD male rats. | 2009 Feb 20 |
|
Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. | 2009 Jun |
|
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. | 2009 Nov 3 |
|
Faster clearance of mirodenafil in rats with acute renal failure induced by uranyl nitrate: contribution of increased protein expression of hepatic CYP3A1 and intestinal CYP1A1 and 3A1/2. | 2009 Oct |
|
Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. | 2009 Sep |
|
Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541. | 2010 |
|
Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. | 2010 Aug |
|
Crystal forms of SK-3530. | 2010 Dec |
|
Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous and oral administration of mirodenafil to streptozotocin-induced diabetes mellitus rats. | 2010 Feb |
|
Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study. | 2010 Sep |
|
Efficacy and safety of mirodenafil in men taking antihypertensive medications. | 2010 Sep |
|
The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury. | 2010 Sep-Oct |
Sample Use Guides
One tablet (Mirodenafil 50mg or 100mg) recommended dosing frequency is once per day. Taken orally approximately 60 minutes before sexual activity. Sexual stimulation is required for a response to treatment.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17640490
The in vitro incubation of [14C]SK-3530 (MIRODENAFIL )with rat and human plasma samples resulted in high protein binding rates of more than 97%; binding was concentration-independent over the range tested (1–100 µmol/L), with no difference between the species show.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 13:59:03 UTC 2023
by
admin
on
Sat Dec 16 13:59:03 UTC 2023
|
Record UNII |
NL7L8TWT8Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
135564928
Created by
admin on Sat Dec 16 13:59:03 UTC 2023 , Edited by admin on Sat Dec 16 13:59:03 UTC 2023
|
PRIMARY | |||
|
876921-44-7
Created by
admin on Sat Dec 16 13:59:03 UTC 2023 , Edited by admin on Sat Dec 16 13:59:03 UTC 2023
|
SUPERSEDED | |||
|
136049
Created by
admin on Sat Dec 16 13:59:03 UTC 2023 , Edited by admin on Sat Dec 16 13:59:03 UTC 2023
|
PRIMARY | |||
|
862189-96-6
Created by
admin on Sat Dec 16 13:59:03 UTC 2023 , Edited by admin on Sat Dec 16 13:59:03 UTC 2023
|
PRIMARY | |||
|
NL7L8TWT8Y
Created by
admin on Sat Dec 16 13:59:03 UTC 2023 , Edited by admin on Sat Dec 16 13:59:03 UTC 2023
|
PRIMARY | |||
|
100000183708
Created by
admin on Sat Dec 16 13:59:03 UTC 2023 , Edited by admin on Sat Dec 16 13:59:03 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |